CDKN2A and primary central nervous system lymphoma: PCNSL cases often carry mutations that lead to activation of the NF-κB pathway, such as activating mutations in MYD88, CDKN2A, TNFAIP3 and CD79B, suggesting that activation of the NF-κB pathway is a key driver of lymphangiogenesis in PCNSL[123, 125–136].